By Scott Tomlins, MD, PhD, Co-Founder & Chief Medical Officer, Strata Oncology Sponsored content brought to you by   At Strata Oncology, we are on a mission to accelerate the impact of precision medicine for patients with cancer, with the ultimate goal of getting every patient their best possible therapy.…

Nearly 15% of all breast cancers diagnosed are tumors in the breast that do not express receptors for estrogen, progesterone, and human epidermal growth factor, dubbed triple negative breast cancer (TNBC). Among one of the hardest form of breast cancer to treat and resistant to conventional chemotherapy, TNBC is closely…

Researchers from AstraZeneca, the University of Oxford, and its spinout company Vaccitech today published preliminary Phase I/II data showing their closely-watched COVID-19 vaccine candidate AZD1222 (formerly ChAdOx1 nCoV-19) to have an acceptable safety profile, and favorable immunogenicity against the virus. “A single dose elicited both humoral and cellular responses against…

23andMe has received a $300 million equity investment disclosed today by GlaxoSmithKline (GSK), under a collaboration designed to use genetic data to identify new drug targets, and thus accelerate development of new therapies for both companies. The collaboration is intended to combine 23andMe’s expertise in gathering and analyzing data from…

The FDA has placed a hold on several mid- and early-stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML) being conducted by Seattle Genetics following the deaths of four patients, the company announced. A Phase I/II trial of SGN-CD33A monotherapy in pre- and post-allogeneic transplant AML patients has…